Crigler-Najjar Syndrome — Clinical Trials

MONDO:00090443 active·3 recruitingLast updated: Mar 16, 2026, 1:17 PM

Trial Landscape

Crigler-Najjar Syndrome has an emerging clinical trial program, driven by drug treatment and gene therapy.

Recruiting

Active Trials

By Approach

Drug Treatment2

Gene Therapy1

By Phase

Phase 1

Phase 2

1 trials are observational or have no phase designation.

Sponsor Types

Academic/Other3

Trial Locations

France2 trials

Italy1 trial

Netherlands1 trial

Russia1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

3 Trials

Phase 2Recruiting

NCT06518005

Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome

Sponsor:GenethonOrphan Designation

FranceStarted: Nov 2024Est. completion: Sep 2030Updated: Dec 2024

Phase 1RecruitingGene Therapy

NCT06641154

Gene Therapy for Crigler Najjar Syndrome Type I (AlphaCN)

Sponsor:Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare

RussiaStarted: Nov 2024Est. completion: Nov 2029Updated: Jan 2025

Not ApplicableRecruitingGene Therapy

NCT03466463

Gene Therapy for Severe Crigler Najjar Syndrome

Sponsor:GenethonOrphan Designation

FranceStarted: Mar 2018Est. completion: Mar 2030Updated: Mar 2023

Last updated over 18 months ago

Stay informed about clinical trials for Crigler-Najjar Syndrome.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 16, 2026 at 1:17 PM